March 15, 2024Open Access

Supplementary Figure S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Key points are not available for this paper at this time.

Supplementary Figure 1. Nonclinical Mechanisms of Potential Ineffective Dual AR/GR Inhibition

Cite This Study